Here's a statement of the obvious: The opinions expressed here are those of the participants, not those of the Mutual Fund Observer. We cannot vouch for the accuracy or appropriateness of any of it, though we do encourage civility and good humor.
As a member of the pharma community there is so much that could be explored about pricing.
#1 Let's dispel with the phony cash goes for development of new drugs. Most of pharma doesn't do basic research. It too risky with little roi. During the '9…
